SCWorx Secures Nasdaq Listing Continuation Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Nasdaq Listing Continuation: SCWorx has received approval from the Nasdaq Hearings Panel to continue its listing, contingent upon meeting specific conditions, demonstrating the company's commitment to compliance amid delisting risks.
- Price Requirement: Trading of SCWorx's stock was suspended on April 14, 2026, due to failure to meet the minimum bid price of $1 per share, necessitating shareholder approval for a reverse stock split by July 22, 2026, to regain compliance.
- Compliance Plan: The company must implement the reverse stock split by August 3, 2026, and prove compliance with the bid price rule by showing a closing bid price of at least $1 per share for 20 consecutive trading days by August 28, 2026, to avoid delisting.
- Strategic Priority: The CEO emphasized that maintaining the Nasdaq listing is a strategic priority, aiming to enhance the healthcare supply chain data management platform through artificial intelligence, thereby creating long-term value for shareholders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
